Identification of a Tripartite Motif Family Gene Signature for Predicting the Prognosis of Patients with Glioma

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2022 Apr 15

PMID 35422900

Authors

Sheng Xiao

Junhua Yu

Xuegang Yuan

Qianxue Chen

Affiliations

Soon will be listed here.

Abstract

Methods: The gene expression RNA-Seq data and corresponding clinical information of glioma patients were obtained from The Cancer Genome Atlas (TCGA) dataset and the Chinese Glioma Genome Atlas (CGGA) dataset. LASSO regression and multivariate Cox regression analyses were performed to construct a risk signature of the TRIM family genes. The accuracy of the risk signature in predicting the prognosis of glioma patients was evaluated. The effects of on glioma cell proliferation were further explored.

Results: We constructed a prognostic signature based on eight TRIMs for the prediction of overall survival of glioma patients. Internal and external cohorts confirmed the satisfactory accuracy and generalizability of the signature in predicting the prognosis of glioma patients. Of the eight TRIMs, was significantly downregulated in glioma, and decreased with an increase in the tumor grade. Moreover, low expression of predicted poor prognosis in glioma. CCK-8 and colony formation assays indicated that overexpression significantly inhibited cell proliferation. Conversely, silencing of had the opposite effects.

Conclusion: Our eight-gene signature based on the TRIM gene family is a novel and clinically useful biomarker, which may be helpful for clinical decision-making. Additionally, might be a therapeutic target for glioma.

Citing Articles

It's a TRIM-endous view from the top: the varied roles of TRIpartite Motif proteins in brain development and disease.

Dudley-Fraser J, Rittinger K Front Mol Neurosci. 2023; 16:1287257.

PMID: 38115822 PMC: 10728303. DOI: 10.3389/fnmol.2023.1287257.

Comprehensive analysis of the prognostic and immunological signature of eight Tripartitemotif (TRIM) family molecules in human gliomas.

Lu J, Liang K, Zou R, Peng Y, Wang H, Huang R Aging (Albany NY). 2023; 15(12):5798-5825.

PMID: 37367937 PMC: 10333093. DOI: 10.18632/aging.204841.

TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Huang N, Sun X, Li P, Liu X, Zhang X, Chen Q Exp Hematol Oncol. 2022; 11(1):75.

PMID: 36261847 PMC: 9583506. DOI: 10.1186/s40164-022-00322-w.

Emerging Roles of TRIM Family Proteins in Gliomas Pathogenesis.

Giannopoulou A, Xanthopoulos C, Piperi C, Kostareli E Cancers (Basel). 2022; 14(18).

PMID: 36139694 PMC: 9496762. DOI: 10.3390/cancers14184536.

Construction and validation of an angiogenesis-related gene expression signature associated with clinical outcome and tumor immune microenvironment in glioma.

Hu T, Wang Y, Wang X, Wang R, Song Y, Zhang L Front Genet. 2022; 13:934683.

PMID: 36035133 PMC: 9403517. DOI: 10.3389/fgene.2022.934683.

References

Gushchina L, Kwiatkowski T, Bhattacharya S, Weisleder N . Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2017; 185:12-25. PMC: 5721676. DOI: 10.1016/j.pharmthera.2017.10.020. View

Valletti A, Marzano F, Pesole G, Sbisa E, Tullo A . Targeting Chemoresistant Tumors: Could TRIM Proteins-p53 Axis Be a Possible Answer?. Int J Mol Sci. 2019; 20(7). PMC: 6479553. DOI: 10.3390/ijms20071776. View

Oberheim Bush N, Chang S, Berger M . Current and future strategies for treatment of glioma. Neurosurg Rev. 2016; 40(1):1-14. DOI: 10.1007/s10143-016-0709-8. View

Mansouri A, Hachem L, Mansouri S, Nassiri F, Laperriere N, Xia D . MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 2018; 21(2):167-178. PMC: 6374759. DOI: 10.1093/neuonc/noy132. View

Magiera M, Mora S, Mojsa B, Robbins I, Lassot I, Desagher S . Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons. Cell Death Differ. 2012; 20(2):281-92. PMC: 3554334. DOI: 10.1038/cdd.2012.124. View

Vicenzi E, Poli G . The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection. Cytokine Growth Factor Rev. 2018; 40:40-47. DOI: 10.1016/j.cytogfr.2018.02.001. View

Wang S, Zhang Y, Huang J, Wong C, Zhai J, Li C . TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression. Cancer Res. 2019; 79(16):4086-4098. DOI: 10.1158/0008-5472.CAN-18-3614. View

Feng S, Cai X, Li Y, Jian X, Zhang L, Li B . Tripartite motif-containing 14 (TRIM14) promotes epithelial-mesenchymal transition via ZEB2 in glioblastoma cells. J Exp Clin Cancer Res. 2019; 38(1):57. PMC: 6364431. DOI: 10.1186/s13046-019-1070-x. View

Micale L, Fusco C, Fontana A, Barbano R, Augello B, De Nittis P . TRIM8 downregulation in glioma affects cell proliferation and it is associated with patients survival. BMC Cancer. 2015; 15:470. PMC: 4468980. DOI: 10.1186/s12885-015-1449-9. View

10.

Li K, Wang F, Cao W, Lv X, Hua F, Cui B . TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. Cancer Cell. 2017; 31(5):697-710.e7. DOI: 10.1016/j.ccell.2017.04.006. View

11.

Tan Z, Song L, Wu W, Zhou Y, Zhu J, Wu G . TRIM14 promotes chemoresistance in gliomas by activating Wnt/β-catenin signaling via stabilizing Dvl2. Oncogene. 2018; 37(40):5403-5415. DOI: 10.1038/s41388-018-0344-7. View

12.

Ji J, Ding K, Luo T, Zhang X, Chen A, Zhang D . TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα. Cell Death Differ. 2020; 28(1):367-381. PMC: 7853150. DOI: 10.1038/s41418-020-00606-w. View

13.

Qazi M, Vora P, Venugopal C, Sidhu S, Moffat J, Swanton C . Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol. 2017; 28(7):1448-1456. DOI: 10.1093/annonc/mdx169. View

14.

Huang R, Li G, Wang Z, Hu H, Zeng F, Zhang K . Identification of an ATP metabolism-related signature associated with prognosis and immune microenvironment in gliomas. Cancer Sci. 2020; 111(7):2325-2335. PMC: 7385348. DOI: 10.1111/cas.14484. View

15.

Cheng J, Fan Y, Liu B, Zhou H, Wang J, Chen Q . ACSL4 suppresses glioma cells proliferation via activating ferroptosis. Oncol Rep. 2019; 43(1):147-158. PMC: 6912066. DOI: 10.3892/or.2019.7419. View

16.

Zhang C, Mukherjee S, Tucker-Burden C, Ross J, Chau M, Kong J . TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3. Mol Oncol. 2017; 11(3):280-294. PMC: 5332279. DOI: 10.1002/1878-0261.12034. View

17.

LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View

18.

Alloush J, Weisleder N . TRIM proteins in therapeutic membrane repair of muscular dystrophy. JAMA Neurol. 2013; 70(7):928-31. PMC: 3746993. DOI: 10.1001/jamaneurol.2013.469. View

19.

Mair M, Geurts M, van den Bent M, Berghoff A . A basic review on systemic treatment options in WHO grade II-III gliomas. Cancer Treat Rev. 2020; 92:102124. DOI: 10.1016/j.ctrv.2020.102124. View

20.

Sang Y, Li Y, Song L, Alvarez A, Zhang W, Lv D . TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3. Cancer Res. 2018; 78(7):1792-1804. PMC: 5882560. DOI: 10.1158/0008-5472.CAN-17-2774. View